ipo
.
Excerpts from CNBC-TV18's exclusive interview with Ajay Piramal: Q: The market would try
to asses the value of your R&D pipeline and estimates range anywhere between
USD 250-500 million by the end of FY09, could you give the markets some
inkling of how to value your pipeline? A: The
pipeline has been independently valued by three of the investment bankers.
They are Lehman Brothers, Kotak and Enam. Their valuation ranges somewhere
from about USD 480 million to about USD 600 million. So, that is one
independent basis of valuation. Lehman
had said that the price according to their estimates should be in a region of
about Rs 750 per share but ultimately the markets will find its own levels.
Q:
Could you also tell us when you are likely to receive the milestone payment
from Eli Lilly, which is an important benchmark that
investors would watch in your stock? A: The
milestone payments as we have worked out with Eli Lilly would be at the end of
each clinical phase. The product has just gone into the first phase of
clinical trials. So at the end of Phase I, we will get some milestone payment.
The next milestone will be at the end of phase II. It will also be taken into
the launch there would be the third and significant milestone along with
royalty payments.
Q: Can
you just confirm the quantum of the milestone payments that you are looking at
though because our estimates throw up that you could get upto USD 110 million?
Is that the first payment you might get, how much do you think that might get
scaled up with and what estimates are you working with? A: We
estimate that over a period of time, we could get milestones in the region
plus we would get royalty on sales on successful launch. Besides Eli Lilly, we
also have almost similar arrangement with Merck also. These two collaborations
can take to a further stage of development.
Q: What
exactly is the agreement with Merck would stand at? What might that throw up
by way of milestone payments? A: In
the agreement with Merck, we will do the development of stage I and stage II.
In stage III of clinical trails, they have an option to do it themselves or we
may continue to do it. There, the milestone payments could be in the region of
about USD 175 million as well as royalty on sales. Also, we will get some
markets where we can sell these products
Excerpts from CNBC-TV18's exclusive interview with Ajay Piramal:
Q: The market would try to asses the value of your R&D pipeline and estimates range anywhere between USD 250-500 million by the end of FY09, could you give the markets some inkling of how to value your pipeline?
A: The pipeline has been independently valued by three of the investment bankers. They are Lehman Brothers, Kotak and Enam. Their valuation ranges somewhere from about USD 480 million to about USD 600 million. So, that is one independent basis of valuation.
Lehman had said that the price according to their estimates should be in a region of about Rs 750 per share but ultimately the markets will find its own levels.
Q: Could you also tell us when you are likely to receive the milestone payment from Eli Lilly, which is an important benchmark that investors would watch in your stock?
A: The milestone payments as we have worked out with Eli Lilly would be at the end of each clinical phase. The product has just gone into the first phase of clinical trials. So at the end of Phase I, we will get some milestone payment. The next milestone will be at the end of phase II. It will also be taken into the launch there would be the third and significant milestone along with royalty payments.
Q: Can you just confirm the quantum of the milestone payments that you are looking at though because our estimates throw up that you could get upto USD 110 million? Is that the first payment you might get, how much do you think that might get scaled up with and what estimates are you working with?
A: We estimate that over a period of time, we could get milestones in the region plus we would get royalty on sales on successful launch. Besides Eli Lilly, we also have almost similar arrangement with Merck also. These two collaborations can take to a further stage of development.
Q: What exactly is the agreement with Merck would stand at? What might that throw up by way of milestone payments?
A: In the agreement with Merck, we will do the development of stage I and stage II. In stage III of clinical trails, they have an option to do it themselves or we may continue to do it. There, the milestone payments could be in the region of about USD 175 million as well as royalty on sales. Also, we will get some markets where we can sell these products
Equity Shares o/s prior to the Issue 2,000,000,000 Equity Shares of Rs 10 each
Equity Shares o/s after the Issue 2,260,000,000 Equity Shares of Rs 10 each
Reliance Power Limited is offering investors the
following benefits:-
RETAIL DISCOUNT- A discount of Rs 20 tothe Issue Price to retailindividual bidders only
PART PAYMENT FACILITY- For both Retail and Non-Institutional BiddersPAYMENT METHOD – 1 - PART PAYMENT FACILITY:-Retail Individual Bidders – at the time of application
PAYMENT METHOD – 2 -
FULL PAYMENTNon Institutional Bidders
Non Institutional Bidders are required to pay Rs 115 per equity share.The
minimum number of shares in the non institutional category is 240 equityshares.
There is no discount (of Rs 20) applicable to this category.Non Residents BiddersNon residents require prior approval from RBI for subscribing to partly paid shares
Retail Individual Bidders
The investor shall make full payment less Rs 20